| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | Concentrations of human IgG in rhesus macaque serum or BALF were determined by an ELISA. Goat anti-human kappa monkey ads-UNLB was coated on the ELISA plate as the capture reagent. For the serum assay, calibrators, controls, and samples in neat serum were diluted 200-fold in PBS casein assay buffer and were transferred to the coated plates. For BALF samples, a 10-fold dilution in PBS casein buffer was used. After incubation, the plate was washed to remove unbound material, and mouse anti-human IgG Fc-HRP was added as detection reagent. After incubation, unbound enzyme was washed away and BioFX 3,3',5,5'-tetramethylbenzidine one-component HRP microwell substrate was added to the wells. Color development was stopped by the addition of phosphoric acid, and the optical density was measured at 450 nm with wavelength correction set to 650 nm. Immunoreactivity was determined from calibrators using a four-parameter logistic regression model with 1/F2 weighting. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
